Investor Relations

MiNK Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class invariant natural killer T (iNKT) cell therapies to transform the lives of patients with cancer.
Press Releases
Jun 05, 2023
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
NEW YORK , June 05, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other
May 18, 2023
MiNK's Novel FAP-CAR-iNKT Presented at ASGCT
FAP-CAR-IL-15 iNKT cell therapy (MiNK-215) promotes curative responses driving tumor elimination and immune infiltration in NSCLC models IND enabling studies underway; IND filing on track for 2024 NEW YORK , May 18, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage
Corporate Presentation

SEC Filings

Form Description Filing date View
SC 13G

A statement of beneficial ownership of common stock by certain persons

 View HTML
0001193125-22-041640.pdf
0001193125-22-041640.rtf
0001193125-22-041640.xls
S-1/A

Amended Registration statement for face-amount certificate companies

 View HTML
0001193125-21-296215.pdf
0001193125-21-296215.rtf
0001193125-21-296215.xls
4/A

Amendment to a previously filed 4

 View HTML
0000950170-23-024556.pdf
0000950170-23-024556.rtf
0000950170-23-024556.xls
4/A

Amendment to a previously filed 4

 View HTML
0000950170-23-024567.pdf
0000950170-23-024567.rtf
0000950170-23-024567.xls

Data provided by Kaleidoscope.

Events and Presentations